"The respective teams at Roquefort Investments and Lyramid believe the Midkine global patent portfolio has significant unrealised value that can be unlocked through pre-clinical drug development utilising oligonucleotide drugs"
Stephen West, Executive Chairman
Roquefort Investments
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable